Biological Sample Collection Kits Market - By Product (Swabs, Viral Transport Media, Blood Collection Kits), By Application (Diagnostics, Research), By End-use (Hospitals and Clinics, Diagnostic Centers, Homecare) & Forecast, 2023 – 2032

Biological Sample Collection Kits Market Size

Biological Sample Collection Kits Market size was valued at around USD 7.8 billion in 2022 and is set to register over 8.8% CAGR between 2023 and 2032. Several factors comprising increasing demand for diagnostic and research applications contribute to this growth. The rising prevalence of chronic & infectious diseases, coupled with advancements in genetic & molecular research has also led to a growing demand for sample collection kits.
 

Personalized medicine that involves tailoring medical treatments to individual patients is gaining traction. Genetic testing and analysis are key components of personalized medicine, and biological sample collection kits play a vital role in obtaining genetic material for analysis. The increasing adoption of personalized medicine is driving the demand for sample collection kits. Further, biobanks that store and manage biological samples for research purposes have witnessed significant growth. These facilities require efficient and standardized sample collection kits to maintain the integrity of the stored samples. Additionally, an increasing number of large-scale research studies and clinical trials contribute to the demand for sample collection kits. As a result, the biological sample collection kits market is expected to continue growing due to the rising demand for diagnostic and research applications, technological advancements, the focus on personalized medicine, and the expansion of research studies among others.
 

Biological sample collection kits are specialized packages or containers that contain the necessary tools and materials for collecting and preserving various types of biological samples for laboratory analysis or research purposes. These kits are designed to ensure the safe and efficient collection of biological specimens while maintaining their integrity and minimizing the risk of contamination.
 

However, the complexities associated with biological sample collection kits may act as a restraint in market revenue. Contamination during sample collection can lead to inaccurate results or false positives/negatives. It requires careful handling of the collection kits, adherence to proper aseptic techniques, and appropriate storage conditions. The accuracy and reliability of the collected samples can be affected by user error during the collection process. Different research areas and diagnostic tests may require specific modifications to collection kits. For instance, kits designed for molecular analysis might need specialized preservatives or additives to stabilize nucleic acids, while kits for microbiological analysis may require specific transport media to maintain bacterial or viral viability. Thus, the complexities associated with biological sample collection kits may obstruct the market growth.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the biological sample collection kits market. The COVID-19 pandemic created a massive demand for diagnostic testing including the collection and analysis of biological samples. This surge in demand led to a substantial increase in the requirement for biological sample collection kits including swabs, vials, transport media, and other associated products. Governments and healthcare organizations globally augmented their testing infrastructure to identify and contain the spread of the virus. This expansion required a corresponding increase in the production and distribution of biological sample collection kits to facilitate mass testing programs. The pandemic stimulated the development of new and improved biological sample collection kits to meet the specific requirements of COVID-19 testing. Hence, the abovementioned attributes had augmented the demand for biological sample collection kits and is expected to witness a similar trend in the coming years.
 

Biological Sample Collection Kits Market Trends

The expansion of biobanking and personalized medicine has been a significant development in the field of healthcare and biomedical research. Biological sample collection kits play a crucial role in biobanking and personalized medicine by facilitating the collection, storage, and analysis of biological samples from individuals. These kits are designed to ensure the proper handling and preservation of various types of samples such as blood, saliva, urine, tissue, and DNA. In biobanking, sample collection kits are used to gather and store biological materials from individuals for research purposes. These samples are often linked to extensive clinical and phenotypic data, creating a valuable resource for studying various diseases, understanding genetic factors, and developing personalized treatments.
 

Biological Sample Collection Kits Market Analysis

Based on product, the biological sample collection kits market is segmented as swabs, viral transport media, blood collection Kits, and others. The swabs segment held the dominant market share in 2022 and was valued at over USD 2.7 billion. The swabs sample collection kits segment has experienced significant growth in recent years, primarily driven by the global COVID-19 pandemic. Swab sample collection kits are essential tools used for diagnostic testing, including PCR and antigen tests, to detect various infectious diseases. During the COVID-19 pandemic, the demand for swabs sample collection kits surged as countries worldwide implemented widespread testing to identify and control the spread of the virus. This rise in demand led to a shortage of swabs and the need to rapidly increase production to meet testing requirements.
 

Based on application, the biological sample collection kits market is segmented as diagnostics and research. The diagnostics segment held a dominant market share in 2022 and was valued at around USD 6.1 billion. Biological sample collection kits are essential tools used in diagnosis and medical research to obtain specimens from patients for testing and analysis. These kits provide standardized and convenient methods for collecting various biological samples, such as blood, urine, saliva, swabs, and tissue samples. For instance, blood collection kits are used to collect blood samples for various tests including complete blood count (CBC), blood chemistry analysis, infectious disease screening, and genetic testing among others. Saliva samples are collected using kits designed specifically for saliva-based testing, including genetic testing, hormone analysis, and infectious disease screening. These kits often include saliva collection tubes or containers, swabs or sponges, and preservatives to stabilize the sample. Hence, the above-mentioned variables are projected to fuel the industry growth over the forecast period.
 

Based on end-use, the biological sample collection kits market is segmented as hospitals and clinics, diagnostic centers, homecare, and others. The hospitals & clinics segment dominated the market in 2022 and is projected to reach USD 11.5 billion by 2032. The soaring use of novel biological sample collection kits in hospital & clinic settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of kits for performing these tests with proven accuracy is set to drive products preference in hospitals & clinics. Growing admissions with infectious & chronic disorders and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment growth positively.
 

The U.S. held a dominant share in the North America biological sample collection kits market and was valued at USD 2.3 billion in 2022. This majority market share is attributable to numerous variables including the presence of key market players, an increase in the prevalence of infectious diseases, and rising awareness regarding early-stage disease diagnosis among others. For instance, according to the Center for Diseases Control Prevention (CDC), in 2019, the human immunodeficiency virus (HIV) affected around 1,189,700 individuals in the U.S. Further, as per the National Hospital Ambulatory Medical Care Survey (NHAMCS) 2020, around 4.3 million people visited the emergency departments for the primary diagnosis of infectious diseases in the U.S. Biological sample collection kits has become a significant diagnostic tool to confirm the presence or absence of such infectious diseases, thereby stimulating the product demand positively.
 

The U.S. has a robust healthcare and biotechnology sector, with significant investments in research and development activities. The increasing focus on drug development, genomics, and personalized medicine has fuelled the demand for biological sample collection kits in the region. Moreover, the U.S. has a well-established regulatory framework for the approval and use of medical devices including sample collection kits. A favourable regulatory environment encourages market players to invest in product development and launch new offerings, further driving market growth. Thus, the above-mentioned factors are projected to boost the U.S. biological sample collection kits market during the analysis timeframe.
 

Biological Sample Collection Kits Market Share

Some of the major market players operating in the biological sample collection kits market are:

• Thermo Fisher Scientific, Inc.
• QIAGEN
• FHoffmann-La Roche Ltd
• Abbott Laboratories
• Becton
• Dickinson and Company
• Laboratory Corporation of America Holdings
• Seegene Inc.
• Medline Industries Inc. 

Major market players are adop

Biological Sample Collection Kits Industry News:

• In July 2021, Abbott launched Panbio COVID-19 Antigen Self-Test for the detection of SARS-CoV-2 virus in children and adults with or without symptoms. This self-test provides quick result within 15 minutes. Abbott Panbio COVID-19 Antigen Self-Test Kit uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen (Ag). This product launch enabled the company to expand its biological sample collection kits product portfolio and increased the revenue generation.
   
• In June 2021, Roche received the CE mark for the SARS-CoV-2 Antigen Self-Test Nasal allowing for rapid self-testing of COVID-19 at home. The SARS-CoV-2 Antigen Self-Test Nasal enabled individuals to test themselves quickly and conveniently for COVID-19 at home using a simple nasal swab. This strategy enabled the company to expand their customer base while strengthening its market position in the Europe.
   

Biological sample collection kits market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Product

• Swabs
  • Nasopharyngeal (NP) Swabs
  • Oropharyngeal (OP) Swabs
  • Nasal Swabs
• Viral Transport Media
• Blood Collection Kits
• Other Consumables

By Application

• Diagnostics
• Research

By End-use

• Hospitals and Clinics
• Diagnostic Centers
• Homecare
• Others  

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Turkey